Efavirenz (Sustiva, Stocrin): Research
- Small Risk of Birth Defects Due to Efavirenz Confirmed in French Cohort (March 20, 2013)
From HIVandHepatitis.com
- Efavirenz Tied to Neurological Birth Defects (March 8, 2013)
From MedPage Today
- Small Risk of Neurological Birth Defects Due to Efavirenz Confirmed in French Cohort (March 6, 2013)
From aidsmap.com
- Long-Term Efavirenz Linked to Worse Neurocognitive Function in U.S. CHARTER Group (March 5, 2013)
From National AIDS Treatment Advocacy Project
- Sustiva, Atripla Tied to Neurologic Toxicity (November/December 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
On TheBodyPRO.com
 Popular HIV Drug May Cause Memory Declines (October 3, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Efavirenz Interaction Studies With TB Compounds Bedaquiline and Delamanid (September/October 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Study Summaries From ICAAC 2012 (September/October 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Efavirenz Levels Variable in Children in the CHAPAS-3 Study (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- 20% People Switch Atripla Due to Efavirenz Side Effects: Late Switches Are Common (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Similar Efficacy and a Few Gender-Related Differences in Side Effects With Rilpivirine Versus Efavirenz at 96 Weeks (January/February 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Five-Year Follow-Up: Isentress Comparable to Sustiva (July 21, 2011)
From AIDSmeds.com
- Edurant and Sustiva Similar, With Some Failure and Safety Differences, in Two-Year Studies (July 21, 2011)
From AIDSmeds.com
- Lopinavir Troughs Lower in Children on Once-Daily Dose With Efavirenz (May/June 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- A Nanoformulation of Paediatric Efavirenz (May/June 2011)
In HIV Treatment Bulletin, from HIV i-Base
- Study Suggests Genetic Tests Could Help Predict Side Effect Risk From Reyataz, Sustiva (January 3, 2011)
A new study published in the Jan. 15 issue of The Journal of Infectious Diseases suggests genetic testing might help predict whether a person will have side effects from some HIV drugs.
From AIDSmeds.com
- Rilpivirine vs. Efavirenz (October 25, 2010)
To read PDF, click here.
In Treatment Update, from Canadian AIDS Treatment Information Exchange
- TMC278 Noninferior to Efavirenz in Naive But With More Virologic Failures (July 22, 2010)
From National AIDS Treatment Advocacy Project
- Switch From Sustiva to Intelence Reduces Central Nervous System Side Effects (July 20, 2010)
From AIDSmeds.com
- Raltegravir vs. Efavirenz: Focus on Lipodystrophy, Lipids and Other Changes (June 30, 2010)
To read PDF, click here.
In Treatment Update, from Canadian AIDS Treatment Information Exchange
On TheBodyPRO.com
- Raltegravir vs. Efavirenz -- Four Years Later (June 30, 2010)
To read PDF, click here.
In Treatment Update, from Canadian AIDS Treatment Information Exchange
On TheBodyPRO.com
|
Advertisement
|
Email
Glossary
